A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Camping World is a moderate buy, hinging on a likely interest rate decline over the next 12-24 months to further reduce ...